Review

Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis

Kuo-Tung Tang 1,2,3, Bo-Chueh Hsu 4 and Der-Yuan Chen 5,6,*

1 Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung 407, Taiwan; dirac1982@vghtc.gov.tw
2 School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
3 Ph.D. Program in Translational Medicine, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan
4 Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital Puli Branch, Nantou 545, Taiwan; vhpld0273@vghtc.gov.tw
5 College of Medicine, China Medical University, Taichung 404, Taiwan
6 Translational Medicine Laboratory, Rheumatology and Immunology Center, China Medical University Hospital, Taichung 404, Taiwan
* Correspondence: d95959@mail.cmuh.org.tw; Tel.: +886-4-22052121 (ext. 4628); Fax: +886-4-22073812

Abstract: Background: Vaccination is one of the most important measures worldwide to halt the spread of the corona virus disease 2019 (COVID-19). However, the efficacy and safety of these vaccines in rheumatic patients are not well explored. Therefore, we conducted a systematic review and meta-analysis. Methods: We performed a literature search of the PubMed and EMBASE databases on 17 November 2021. Forty-seven studies relevant to the immunogenicity, efficacy/effectiveness, and safety of COVID-19 vaccines were selected. Results: Our results demonstrated that COVID-19 vaccination is effective in protecting rheumatic patients from severe illness caused by the virus. Both the humoral and cellular immunogenicity of vaccines were impaired in rheumatic patients, which were greatly enhanced after the second vaccine dose. Receiving anti-CD20 therapy was associated with impaired humoral immunogenicity. Adverse events due to COVID-19 vaccines in rheumatic patients were similar to those in healthy controls, except for an increased incidence of arthralgia. The incidence of disease flares after COVID-19 vaccination was low. Conclusion: Our systematic review indicated the importance of full vaccination in rheumatic patients. Withholding anti-CD20 therapy was found to be potentially beneficial for the immunogenicity. Furthermore, the vaccines were found to be safe in general. Despite significant heterogeneity between studies, we recommend that rheumatic patients receive these vaccines amidst the global pandemic.

Keywords: adverse events; COVID-19 vaccine; flare; immunogenicity; rheumatic disease; safety

1. Introduction

Since the initial outbreak in December 2019, the coronavirus disease 2019 (COVID-19) pandemic has placed a tremendous burden on healthcare systems and is still a huge threat to all human beings. As of 31 December 2021, nearly 285 million cases have been diagnosed, and 5.1 million fatalities reported globally. The severity of the disease may be alleviated by the global application of effective and safe vaccinations [1]. The mRNA and recombinant adenovirus formats are novel vaccine technologies; however, only healthy or immunocompetent adults were systemically assessed for immunogenicity and the safety of COVID-19 vaccines in phase I, II, and III clinical trials [2–10]. To date, very few phase IV clinical trials have been conducted to evaluate the immunogenicity and safety of vaccines for patients with rheumatic diseases [11–14].
Increasing evidence indicates that COVID-19 poses a higher risk for rheumatic patients of more severe disease and mortality, which include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, and idiopathic inflammatory myositis, compared with healthy individuals [15–17]. However, the safety profile of COVID-19 vaccines has been relatively unexplored in rheumatic patients, and multiple studies have demonstrated that the immunogenicity of vaccines may be attenuated by the use of certain immunosuppressants or biologics [13,18–22]. While making efforts in terms of widespread vaccination, physicians also need to understand the immunogenicity and adverse effects of vaccines in such patients, including the possibility of vaccine-induced exacerbation of pre-existing rheumatic diseases. Therefore, we aim to update the evidence of immunogenicity, efficacy/effectiveness, and safety of COVID-19 vaccines in rheumatic patients. Hopefully, our results will have beneficial clinical implications for these vulnerable populations.

2. Materials and Methods
2.1. Literature Search

The present review focuses on existing evidence of the immunogenicity and safety profile of COVID-19 vaccines in rheumatic patients. The algorithm of the systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. We searched the EMBASE and MEDLINE databases. We reviewed English literature from 1 January 2020 to 17 November 2021. The search keywords for COVID-19 vaccines included those on the World Health Organization (WHO) list: mRNA-1273 (Moderna, Cambridge, MA, USA), BNT162b2 (Pfizer–BioNTech, Mainz, Germany), Ad26.COV2.S. (Johnson & Johnson–Janssen, New Brunswick, NJ, USA), AZD1222 (AstraZeneca, Cambridge, UK), Covaxin (Bharat Biotech, Hyderabad, India), BBIBP-CorV (Sinopharm, Beijing, China) and CoronaVac (Sinovac, Beijing, China). The keywords for rheumatic diseases include inflammatory arthritis, SLE, Sjogren’s syndrome, systemic sclerosis, idiopathic inflammatory myositis, antiphospholipid syndrome, vasculitis, cryoglobulinemia, adult-onset Still’s disease, and fibromyalgia. The details of the search strategy are illustrated in Supplementary Table S1. Eventually, we identified a total of 47 studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Figure 1).}

![Figure 1. Flow diagram based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.](image-url)
2.2. Study Selection

Three authors (KT Tang, BC Hsu, and DY Chen) independently assessed the titles and abstracts identified by the search mentioned above and retrieved the relevant full-text articles. Two authors (KT Tang and DY Chen) independently evaluated the full-text articles for eligibility. We selected potentially relevant articles on immunogenicity, efficacy/effectiveness, and/or safety of COVID-19 vaccines in rheumatic patients, including trials, cohorts, cross-sectional and case-control studies involving equal to or more than 10 patients.

2.3. Data Extraction

Information regarding humoral and/or cellular immunogenicity, efficacy/effectiveness, local/systemic adverse effects, and disease flares after COVID-19 vaccination were recorded for each study in a standardized Excel file. The influence of relevant drugs, including corticosteroids, conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) such as Janus kinase inhibitors (JAKi), and other immunosuppresants, were also documented.

2.4. Statistical Analysis

A statistical analysis was performed using Stata, version 14.0 (StataCorp, College Station, TX, USA). A summary estimate of proportions was derived using the command “metaprop” in a random-effects model. The confidence interval was based on the binomial distribution. The summary estimates of rate ratios (RRs) between rheumatic patients and healthy controls, and between drug users and non-users, were derived using the “metan” command. A random-effects model was used following the procedure of DerSimonian and Laird [23]. The heterogeneity was quantified using Tau^2, Chi^2, and I^2 measures, based on the Mantel-Haenszel model. Begg’s and Egger’s tests were used to assess publication bias, while funnel plots were constructed to visualize asymmetry with respect to immunogenicity and disease flares after COVID-19 vaccination.

3. Results
3.1. Study Characteristics

The characteristics of the selected studies are demonstrated in Table 1. Most studies were conducted in Western countries and involved Caucasians. In most studies, female adults were predominant, and only one study focused on adolescents [24]. Most study participants received the BNT162b2 vaccine and only a few studies reported on viral vector-based or inactivated vaccines. In terms of rheumatic diseases, inflammatory arthritis and RA in particular constituted the majority of participants in most studies. Twenty-five studies investigated humoral immunogenicity, whereas cellular immunogenicity was less studied, with only seven relevant studies available. Twenty-seven studies documented adverse events based on either clinical records or questionnaires.
| Author                  | Country       | Sample Size of Rheumatic Patients (n) | Proportion of Female | Mean/Median Age (Years) | Vaccine | Rheumatic Diseases | Humoral Immunogenecity Measurement | Cellular Immunogenecity Measurement | Documentation of Adverse Events |
|-------------------------|---------------|--------------------------------------|----------------------|-------------------------|---------|--------------------|------------------------------------|-----------------------------------|----------------------------------|
| Ammitzbøll et al. [25]  | Denmark       | 134                                  | 72%                  | 66                      | BNT     | RA 54%, and SLE 46% | Anti-SARS-CoV-2 antibody CLIA (Ortho Clinical Diagnostics) | N.A.                              | N.A.                             |
| Barbhaiya et al. [26]   | USA           | 1101                                 | 81%                  | 61                      | BNT     | BNT 54%, Moderna 44%, J&J 2%, and AZ 0.3% | N.A.                              | N.A.                              | N.A.                             | Online survey                   |
| Bartels et al. [27]     | Denmark       | 282                                  | 79%                  | 59                      | BNT     | RA 55%, and SLE 45% | N.A.                              | N.A.                              | N.A.                             | Questionnaire                    |
| Benucci et al. [28]     | Italy         | 14                                   | N.A.                 | 57                      | BNT     | RA                 | Anti-RBD IgG antibodies FEIA (ThermoFisher) IGRA (Euroimmun) | N.A.                              |                                  |
| Bixio et al. [29]       | Italy         | 77                                   | 81%                  | 62                      | BNT     | RA                 | N.A.                              | N.A.                              | Clinical record                  |
| Boekel et al. [30]      | Netherlands   | 505                                  | 65%                  | 64                      | AZ 46%, BNT 41%, and Moderna 13% | RA 40%, PsA 10%, and MS 16% | N.A.                              | N.A.                              | Online questionnaire             |
| Boekel et al. [31]      | Netherlands   | 632                                  | 67%                  | 63                      | AZ 54%, BNT 38%, and Moderna 8% | RA 41%, PsA 11%, AS 11%, and MS 9% | Anti-RBD IgG antibody ELISA (in-house) | N.A.                              | N.A.                             |
| Boyarsky et al. [32]    | USA           | 123                                  | 95%                  | 50                      | BNT 52%, and Moderna 48% | Inflammatory arthritis 28%, overlap syndrome 29%, SLE 20%, and PSS 13% | Anti-RBD antibody ECLIA (Roche) | N.A.                              | N.A.                             |
| Braun-Moscovici et al.  | Israel        | 264                                  | 76%                  | 58                      | BNT     | RA 37%, PsA 12%, and SpA 8% | Anti-RBD IgG CLIA (Abbott) | N.A.                              | Clinical record                  |
| Author               | Country | Sample Size of Rheumatic Patients (n) | Proportion of Female | Mean/Median Age (Years) | Vaccine | Rheumatic Diseases | Humoral Immunogenicity Measurement | Cellular Immunogenicity Measurement | Documentation of Adverse Events |
|---------------------|---------|--------------------------------------|----------------------|-------------------------|---------|-------------------|-----------------------------------|----------------------------------|-------------------------------|
| Bugatti et al. [34] | Italy   | 140                                  | 68%                  | 56                      | BNT     | RA 59%, PsA 21%, and SpA 20% | Anti-S1/S2 protein antibodies IgG CLIA (DiaSorin) | N.A.                             | N.A.                           |
| Cherian et al. [35] | India   | 513                                  | 83%                  | 58                      | AZ      | RA 44%, inflammatory arthritis 16%, SpA 13%, and SLE 10% | N.A.                             | N.A.                             | Clinical record               |
| Chiang et al. [36]  | USA     | 1039                                 | 94%                  | 46                      | mRNA vaccines 96%, and J&J 4% | Inflammatory arthritis 44%, overlap syndrome 21%, SLE 21%, and PSS 5% | Anti-RBD antibody ECLIA (Roche) | N.A.                             | N.A.                           |
| Connolly et al. [37] | USA     | 1377                                 | 92%                  | 47                      | BNT     | Inflammatory arthritis 47%, SLE 20%, and overlap syndrome 20% | N.A.                             | N.A.                             | Online questionnaire           |
| Cuomo et al. [38]   | Italy   | 27                                   | 78%                  | 49                      | BNT     | Inflammatory arthritis 48%, RA 22%, and SSc 19% | N.A.                             | N.A.                             | Telephone interview           |
| Deepak et al. [39]  | USA     | 133                                  | 74%                  | 46                      | mRNA vaccines | IBD 32%, RA 29%, SpA 15%, and SLE 11% | Anti-S protein IgG ELISA (in-house) | N.A.                             | N.A.                           |
| Delvino et al. [40] | Italy   | 81                                   | 68%                  | 76                      | BNT     | GCA                             | N.A.                             | N.A.                             | Written questionnaire          |
| Dimopoulou et al. [24] | Greece | 21                                   | 76%                  | 17                      | BNT     | JIA                             | N.A.                             | N.A.                             | N.A.                           |
Table 1. Cont.

| Author               | Country | Sample Size of Rheumatic Patients (n) | Proportion of Female | Mean/Median Age (Years) | Vaccine | Rheumatic Diseases | Humoral Immunogenecity Measurement | Cellular Immunogenecity Measurement | Documentation of Adverse Events |
|----------------------|---------|--------------------------------------|----------------------|-------------------------|---------|-------------------|-----------------------------------|----------------------------------|-------------------------------|
| Embi et al. [41]     | USA     | 5024                                 | N.A.                 | N.A.                    | Moderna, and BNT | 40% and BNT 60% | Rheumatic or inflammatory disorders | N.A.                            | N.A.                          | N.A.                          |
| Esquivel-Valerio et al. [42] | Mexico | 225                                  | 95%                  | 51                      | BNT (48%), Convidecia (13%), Moderna (13%), AZ (12%), CoronaVac (10%), and J&J (2%) | RA (59%), SLE (11%), and axial SpA (10%) | N.A.                            | N.A.                            | Survey                        |
| Ferri et al. [43]     | Italy   | 478                                  | 84%                  | 59                      | BNT (94%), and Moderna (6%) | SSC (55%), RA (21%), CV (13%), and SLE (8%) | Anti-S1/S2 protein antibodies IgG CLIA (Abbott) | N.A.                            | Telephone interview             |
| Firinu et al. [44]    | Italy   | 95                                   | 73%                  | 56                      | BNT | SLE (24%), RA (24%), PsA, PsO and AS (25%) | Anti-RBD IgG CLIA (Snibe Diagnostics) | N.A.                            | N.A.                          |
| Fragoulis et al. [45] | Greece  | 441                                  | 76%                  | 56                      | BNT (86%), AZ (10%), Moderna (3%), and J&J (1%) | Inflammatory arthritis (59%), CTD (27%), and vasculitis (11%) | N.A.                            | N.A.                            | Telephone interview             |
| Furer et al. [13]     | Israel  | 686                                  | 69%                  | 59                      | BNT | RA (38%), PsA (24%), SLE (15%), vasculitis (10%), and SpA (10%) | Anti-S1/S2 protein antibodies IgG CLIA (DiaSorin) | N.A.                            | Telephone questionnaire         |
| Geisen et al. [22]    | Germany | 26                                   | 64%                  | 51                      | BNT, Moderna (19%) | RA (31%), PsO (12%), SpA (12%), and IBD (12%) | Anti-SARS-CoV-2 ELISA (Euroimmun) | N.A.                            | Online survey                   |
### Table 1. Cont.

| Author                  | Country  | Sample Size of Rheumatic Patients (n) | Proportion of Female | Mean/Median Age (Years) | Vaccine | Rheumatic Diseases | Humoral Immunogenecity Measurement | Cellular Immunogenecity Measurement | Documentation of Adverse Events |
|-------------------------|----------|--------------------------------------|----------------------|-------------------------|---------|-------------------|------------------------------------|-----------------------------------|-------------------------------|
| Haberman et al. [46]    | USA      | 51                                   | 71%                  | 56                      | BNT     | RA 43%, and PsO/PsA 47% | Anti-S1 protein antibody ELISA (in-house) | N.A.                              | N.A.                          |
| Germany                 |          | 31                                   | 71%                  | 51                      | BNT     | GCA and PMR         | Anti-S1 protein antibody ELISA (Euroimmun) | N.A.                              | N.A.                          |
| Izmirly et al. [47]     | USA      | 90                                   | 88%                  | 46                      | BNT     | BNT 68%, Moderna 15%, and J&J 5.5% | Anti-RBD IgG ELISA (in-house) | IFN-γ ELISpot assay (in-house) | N.A.                          |
| Kant et al. [48]        | USA      | 48                                   | 35%                  | 67                      |         | Moderna 52%, BNT 40%, and J&J 8% | AAV                               | N.A.                              | N.A.                          |
| Li et al. [49]          | Hong Kong| 1324                                 | 75%                  | 58                      |         | CoronaVac 51%, and BNT 49%, RA | N.A.                              | N.A.                              | Clinical record              |
| Machado et al. [50]     | EULAR COVID-19 Vaccination Registry | 1519                  | 68%                  | 63                      | BNT     | Inflammatory arthritis 51%, CTD 19%, and vasculitis 16% | N.A.                              | N.A.                              | Clinical record              |
| Medeiros-Ribeiro et al. [12] | Brazil | 910                                  | 77%                  | 51                      | CoronaVac | Inflammatory arthritis 50% | Anti-S1/S2 protein antibodies IgG CLIA (DiaSorin) | N.A.                              | Diary                        |
| Moyon et al. [51]       | France   | 126                                  | 91%                  | 47                      | BNT     | SLE                | SARS-CoV-2 multi-antigenphotonic ring immunoassay(Genalyte) | IGRA (Qiagen)                     | Clinical record              |
| Author                          | Country    | Sample Size of Rheumatic Patients ($n$) | Proportion of Female | Mean/Median Age (Years) | Vaccine | Rheumatic Diseases                                                                 | Humoral Immunogenecity Measurement | Cellular Immunogenecity Measurement | Documentation of Adverse Events |
|--------------------------------|------------|----------------------------------------|----------------------|-------------------------|---------|-------------------------------------------------------------------------------------|-----------------------------------|----------------------------------|---------------------------------|
| Mrak et al. [52]               | Austria    | 45                                     | 78%                  | 64                      | BNT 82%, and Moderna 18% | RA 53%, CTD 27%, and vasculitis 16% | N.A.                             | IFN-γ ELISpot assay (in-house)   | N.A.                            |
| Papagoras et al. [53]          | Greece     | 48                                     | 69%                  | 51                      | BNT 79%, and AZ 21% | Inflammatory arthritis 58%, CTD and vasculitis 40% | N.A.                             | N.A.                            | N.A.                            |
| Picchianti-Diamanti et al. [54]| Italy      | 35                                     | 77%                  | 59                      | BNT                  | RA                                    | Anti-RBD IgG CLIA (Abbott) | IFN-γ whole-blood assay (in-house) | N.A.                            |
| Prendecki et al. [19]          | UK         | 119                                    | 48%                  | 53                      | mRNA vaccines 71%, and AZ 29% | AAV/anti-GBM 38%, MCD/FGS 24%, MGN 19%, and SLE 16% | Anti-S1/S2 protein antibodies IgG CLIA (Abbott) | T SPOT (Oxford Immunotec) | N.A.                            |
| Rotondo et al. [55]            | Italy      | 137                                    | 70%                  | 57                      | BNT 78%, and AZ 22% | Arthritis 78%, and CTD 18%             | N.A.                             | N.A.                            | Questionnaire                   |
| Rubbert-Roth et al. [56]       | Switzerland| 53                                     | 55%                  | 65                      | BNT 83%, and Moderna 17% | RA                                    | Anti-RBD antibody ECLIA (Roche) | N.A.                            | N.A.                            |
| Ruddy et al. [57]              | USA        | 404                                    | 96%                  | 44                      | Moderna 51%, and BNT 49% | Inflammatory arthritis 45%, and SLE 22% | Anti-RBD antibody ECLIA (Roche) | N.A.                            | N.A.                            |
| Sattui et al. [58]             | Global RheumatologyAlliance | 2860                  | 87%                  | 55                      | BNT 53%, AZ 23%, Moderna 21%, and [J&J 2% | RA 42%, IIM 17%, PSS 15%, and SLE 14% | N.A.                             | N.A.                            | Online survey                   |
| Schniedeberg et al. [59]       | Switzerland| 17                                     | 47%                  | 67                      | BNT 82%, and Moderna 12% | RA                                    | Anti-RBD antibody ECLIA (Roche) | N.A.                            | N.A.                            |
| Author               | Country     | Sample Size of Rheumatic Patients (n) | Proportion of Female | Mean/Median Age (Years) | Vaccine       | Rheumatic Diseases                                                                 | Humoral Immunogenecity Measurement | Cellular Immunogenecity Measurement | Documentation of Adverse Events |
|---------------------|-------------|--------------------------------------|----------------------|-------------------------|--------------|-------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|---------------------------------|
| Sciascia et al. [60] | Italy       | 102                                  | 85%                  | 52                      | BNT 66%, and Moderna 34% | APS 51%, and aPL 49%                                                             | N.A.                              | N.A.                              | Clinical record                 |
| Seyahi et al. [61]  | Turkey      | 104                                  | 66%                  | 48                      | CoronaVac               | SpA 23%, RA 18%, CTD 16%, BS 14%, and FMF 10%                                    | Anti-RBD antibody ECLIA (Roche)    | N.A.                              | N.A.                            |
| Simon et al. [62]   | Germany     | 84                                   | 66%                  | 53                      | BNT                     | SpA 32%, RA 30%, IBD 10%, and PsO 10%                                             | Anti-S1 protein antibody ELISA (Euroimmun) | N.A.                              | Clinical record                 |
| Spiera et al. [59]  | USA         | 89                                   | 76%                  | 61                      | BNT 57%, and Moderna 43% | RA 26%, GPA 13%, PSS 11%, and SLE 10%                                           | Anti-RBD antibody ECLIA (Roche)    | N.A.                              | N.A.                            |
| Tzioufas et al. [63] | Greece     | 605                                  | 71%                  | 58                      | BNT 95%, and Moderna 5% | RA 28%, seronegative arthritis 21%, SLE 20%, and vasculitis 11%                  | Anti-S1 protein antibody ELISA (Euroimmun) | N.A.                              | Questionnaire                   |
| Yang et al. [64]    | USA         | 70                                   | 69%                  | 48                      | mRNA vaccines           | RA 30%, SpA 30%, SLE 11%, and IBD 10%                                            | N.A.                              | N.A.                              | Clinical record                 |
| Zavala-Flores et al. [65] | Peru     | 100                                  | 94%                  | 39                      | BNT                     | SLE                                                                            | N.A.                              | N.A.                              | Clinical record                 |

AAV, antineutrophil cytoplasmic antibody-associated vasculitis; aPL, antiphospholipid antibodies positivity; APS, antiphospholipid syndrome; AS, ankylosing spondylitis; AZ, AZD1222; BNT, BNT162b2; BS, Behcet’s syndrome; CLIA, chemiluminescent immunoassay; CTD, connective tissue disorder; CV, cryoglobulinemic vasculitis; ECLIA, electrochemiluminescence immunoassay; ELISA, enzyme-linked immunosorbent assay; ELISpot, Enzyme-linked immunospot; FEIA, fluorescent enzyme immunoassay; FMF, familial mediterranean fever; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; GCA, giant cell arteritis; GPA, granulomatosis with polyangiitis; IBD, inflammatory bowel disease; IFN, interferon; IGRA, interferon-γ release assay; IIM, idiopathic inflammatory myositis; J&J, Ad26.COV2.S.; JIA, juvenile idiopathic arthritis; MCD, minimal change disease; MGN, membranous glomerulonephritis; Moderna, mRNA-1273; MS, multiple sclerosis; N.A., not available; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; PsO, psoriasis; PSS, primary Sjogren’s syndrome; RA, rheumatoid arthritis; RBD, receptor-binding domain; SLE, systemic lupurs erythematosus; SpA, spondyloarthropathy; SSc, systemic sclerosis.
3.2. Immunogenicity of COVID-19 Vaccines in Rheumatic Patients

Humoral response (seroconversion) and T cell response rates after mRNA-based vaccination in rheumatic patients are summarized in Figure 2a. Only 53 (95%CI: 27, 78)% achieved seroconversion after the first dose, although the proportion increased to 79 (95%CI: 67, 89)% after the second dose. The T cell response rate was 57 (95%CI: 43, 71)% after the first dose and, similarly, increased to 69 (95%CI: 55, 81)% after the second dose. Few studies have demonstrated immunogenicity after receiving other vaccines. The seroconversion rate after the first dose of AZD1222 was 49 (95%CI: 44, 54)%, and those after the first and second doses of CoronaVac were 19 (95%CI: 16, 22)% and 70 (67, 73)% respectively [12,31]. The seroconversion rate after Ad26.COV2.S was 80 (95% CI: 65, 90)% [36]. Notably, Schmiedeberg et al. found that a third dose of mRNA vaccine led to a seroconversion rate of 88% (15/17) in RA patients who had no or minimal serological response after two doses [59]. The RRs between rheumatic patients and healthy controls in terms of immunogenicity after COVID-19 vaccination are illustrated in Figure 2b. The RRs for the seroconversion after the first and second dose were 0.42 (95%CI: 0.34, 0.52) and 0.86 (95%CI: 0.84, 0.87), respectively. The RRs for the T cell response after the first and second dose were 0.69 (95%CI: 0.68, 0.69) and 0.86 (95%CI: 0.55, 1.36), respectively. It is worth noting that seroconversion was absent in a few patients receiving anti-CD20 therapy, whereas T cell response could still be elicited in these patients [28,52].

![Figure 2. Cont.](image-url)
3.3. Influencing Factors of Immunogenicity after COVID-19 Vaccination in Rheumatic Patients

The seroconversion rates after the second dose of mRNA vaccines in certain medication users are illustrated in Figure 3a. The use of mycophenolic acid or anti-CD20 therapy was associated with a lower seroconversion rate, i.e., 66 (95%CI: 57, 73)% and 41 (95%CI: 35, 48)%, respectively. The seroconversion rate ratios between medication users and non-users among rheumatic patients after the second dose of mRNA vaccines are illustrated in Figure 3b. The use of corticosteroids, mycophenolic acid, or anti-CD20 therapy was associated with a lower seroconversion rate when compared with non-users. In particular, anti-CD20 therapy was associated with a seroconversion rate that was 55% lower than that of non-users. Additionally, some other factors were found to be associated with a lower seroconversion rate, as summarized in Table 2. To be noted, Bugatti et al. found that withholding methotrexate or b/tsDMARD for a short time did not significantly influence the seroconversion rate [34].

Table 2. Factors other than medication use that were associated with a lower seroconversion rate after COVID-19 vaccination in rheumatic patients.

| Factors                                                                 |
|------------------------------------------------------------------------|
| Older age                                                              |
| Lower B lymphocyte count                                                |
| Lower serum IgG                                                        |
| Shorter interval between vaccination and last infusion of anti-CD20 therapy |
| Not achieving B cell reconstitution after anti-CD20 therapy             |
Figure 3. Cont.
Figure 3. (a) Seroconversion rates after the second dose of mRNA vaccines in certain medication users, and (b) the seroconversion rate ratios between medication users and non-users in rheumatic patients. The black squares represent the effect estimates of the individual studies and the diamonds represent the summary effect estimates. IL, interleukin; JAK, Janus kinase; TNF, tumor necrosis factor.
3.4. Effectiveness of COVID-19 Vaccines in Rheumatic Patients

Only two retrospective studies demonstrated the effectiveness of COVID-19 vaccines in rheumatic patients. Papagoras et al. showed that the hospitalization and mortality rates were higher in unvaccinated (29% and 4%) than the fully vaccinated rheumatic patients (10% and 0%) [53]. In another study, the effectiveness of two doses of mRNA vaccines against COVID-19 hospitalization was 81%, which was slightly lower than that (90%) of immunocompetent controls [41].

3.5. Adverse Events of COVID-19 Vaccines in Rheumatic Patients

The incidence rates of adverse events after COVID-19 vaccination are illustrated in Figure 4a, b. Local pain (30-55%) was the most common, followed by fatigue (19-28%) after the first dose of viral vector-based vaccine or both doses of the BNT162b2 vaccine. A total of two (0.04%) serious adverse events developed in 4433 rheumatic patients after COVID-19 vaccination. The incidence rate ratios of adverse events after the first dose of COVID-19 vaccines between rheumatic patients and healthy controls are illustrated in Figure 4c. Compared with healthy controls, local pain was less common, whereas arthralgia was more common after receiving the BNT162b2 vaccine, and fever and myalgia were less frequent after viral vector-based vaccination in rheumatic patients.

![Figure 4. Cont.](image-url)
Figure 4. The incidence rate of adverse events after the (a) first and (b) second dose of COVID-19 vaccines in rheumatic patients, and the (c) incidence rate ratios of adverse events after the first dose of COVID-19 vaccines between rheumatic patients and healthy controls. The black squares represent the effect estimates of the individual studies and the diamonds represent the summary effect estimates.
3.6. The Influence of COVID-19 Vaccines on Disease Activity of Rheumatic Diseases

As illustrated in Figure 5, around 2–3% of rheumatic patients developed a flare after COVID-19 vaccination. The disease activity measures, such as disease activity score (DAS)28 and Systemic Lupus Disease Activity Index (SLEDAI), etc., were not different before and after the vaccination [13,33,51].

Figure 5. The incidence rate of disease flares after COVID vaccination. The black squares represent the effect estimates of the individual studies and the diamonds represent the summary effect estimates.

3.7. Publication Bias

Visual inspection of funnel plots demonstrated the existence of potential publication biases with regards to seroconversion rate and rate ratios after mRNA vaccines and the proportion of disease flares after vaccination, although the Begg’s and Egger’s test results did not reach statistical significance (Supplementary Figures S1 and S2).

4. Discussion

Efficacious COVID-19 vaccination is needed to contain the ongoing pandemic. However, a comprehensive evidence analysis or consensus regarding the efficacy and safety of COVID-19 vaccines in rheumatic patients is lacking to date. According to our review, despite the impaired immunogenicity of vaccines in these patients, the vaccines were still very effective in reducing hospitalization and mortality. There were no new safety signals for these vaccines in rheumatic patients except for arthralgia. In addition, the risk of a disease flare after vaccination was minimal.
Being immunocompromised due to inherent immune dysregulation and the concomitant use of immunosuppressants, rheumatic patients are more vulnerable to severe or opportunistic infections. During the COVID-19 pandemic, rheumatic patients were more likely to be hospitalized or succumb [15,66], and were strongly advised to receive COVID-19 vaccination [67]. We found that rheumatic patients had impaired humoral and cellular immune responses after COVID-19 vaccination, which was consistent with previous observations of poorer responses to different kinds of vaccines [68]. However, the second or even third dose seemed to significantly enhance the immunogenicity of COVID-19 vaccines. Furthermore, retrospective studies revealed that vaccination was still highly effective against severe illness when contracting COVID-19 for rheumatic patients, supporting the importance of full vaccination.

Immunosuppressants and bDMARDs, including methotrexate, abatacept, and anti-CD20 therapy (rituximab), have been shown to impair vaccine response in rheumatic patients [68,69]. In the present meta-analysis, we found impaired humoral response in patients receiving anti-CD20 therapy. In addition, several studies demonstrated that other B lymphocyte-associated factors were also implicated in poor humoral response after COVID-19 vaccination. Therefore, it is better to postpone anti-CD20 therapy until B lymphocytes reconstitution before COVID-19 vaccination. On the other hand, the use of mycophenolic acid was also associated with impaired humoral response after COVID-19 vaccination, which was similarly found in transplantation patients [70,71]. Although withholding most of these immunosuppressants before vaccination was generally recommended [67], we did not find sufficient evidence to support the beneficial effect of such measures, probably due to very few related study results. The only exception was anti-CD20 therapy, in which the interval between the last infusion and COVID-19 vaccination was positively associated with increased humoral response. More studies are required to provide evidence in terms of deciding which medications to withhold and the optimal time frame.

Vaccine hesitancy has led some rheumatic patients to abstain from vaccination, putting them at an unnecessary risk for COVID-19. The two main reasons for hesitation were adverse events and worries about flares of underlying diseases [72]. Our review seeks to reassure such individuals that no new safety signal has been found in rheumatic patients receiving vaccination except for arthralgia after receiving the BNT162b2 vaccine, and most of these joint symptoms were transient and lasted for a few days. The rate of serious adverse events was extremely low after COVID-19 vaccination, i.e., comparable to that in the general population [73]. Additionally, the incidence rate of disease flare after vaccination was also low, and there was, on average, no increase in disease activity in most rheumatic patients.

Our review has some limitations. First, the study population, comorbidities, concomitant medication use, interval between vaccination and outcomes, and outcome measurements differed considerably among studies. Such heterogeneity limited the strength of the interpretation of the results. Furthermore, the combination of several medications precluded the precise determination of the effect of a single drug in terms of immunogenicity. Second, underrepresentation of ethnic groups such as Asians and Hispanics, age groups such as adolescents and children, receivers of non-mRNA vaccines, and patients with rheumatic diseases other than inflammatory arthritis should cause some concern when extrapolating our findings. Third, we found that the humoral immune response was more impaired than the cellular response in rheumatic patients after COVID-19 vaccination. Could such preserved cellular response protect these patients from COVID-19 infection? A relatively small number of effectiveness studies suggested an urgent need to conduct more such studies to elucidate this question and find other influencing factors (such as medications). Fourth, the duration of medication use was not specified in these studies. For instance, the duration of corticosteroid use may affect vaccine efficacy. Despite these limitations, our review still provides an updated and valuable overview of effectiveness and safety issues while rheumatic patients worldwide are receiving vaccinations due to the COVID-19 pandemic. Moreover, our results were similar to those of studies on patients
with multiple sclerosis, an autoimmune neurological disorder which is treated with similar drugs [74,75].

5. Conclusions

Our comprehensive review demonstrated the efficacy, albeit lower when compared with healthy individuals, and safety of COVID-19 vaccines in rheumatic patients. The results support the recommendations of full vaccination in these patients. However, significant study heterogeneity may undermine our conclusions.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/biomedicines10040834/s1, Figure S1: The funnel plots, as well as Begg’s and Egger’s tests results, of the seroconversion rate and cellular response rate after (a, b) 1st and (c, d) 2nd dose of mRNA vaccines, and (e) the proportion of disease flares after COVID-19 vaccination, Figure S2: Begg’s and Egger’s tests results, of the seroconversion rate ratios after (a) 1st and (b) 2nd dose of mRNA vaccines when compared with healthy controls, Table S1: Search strategies.

Author Contributions: K.-T.T. conceived and designed the study, performed the literature search, retrieved the relevant full-text articles, evaluated their eligibility for this review, summarized the existing evidence, and drafted the manuscript. B.-C.H. performed the literature search, retrieved the relevant full-text articles, and evaluated their eligibility for this review. D.-Y.C. conceived and designed the study, performed the literature search, retrieved the relevant full-text articles, evaluated their eligibility for this review, appraised the selected articles, summarized the existing evidence, and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a grant from China Medical University Hospital (DMR-110-021), and by the grant (MOST 110-2314-B-039-051) from the Ministry of Science and Technology, Taiwan.

Informed Consent Statement: Informed consent was not needed because this is a systemic review.

Data Availability Statement: The datasets used and/or analyzed during the current review are available from the corresponding author on reasonable request.

Acknowledgments: The authors thank Shiow-Jiuan Wey, of the Chung Shan Medical University Hospital, Taiwan, for the help in manuscript preparation.

Conflicts of Interest: The authors have no competing interest to declare.

References
1. Sadarangani, M.; Marchant, A.; Kollmann, T.R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 2021, 21, 475–484. [CrossRef] [PubMed]
2. Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467–478. [CrossRef]
3. Jackson, L.A.; Anderson, E.J.; Rouphael, N.G.; Roberts, F.C.; Makhene, M.; Coler, R.N.; McCullough, M.P.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; et al. An mRNA Vaccine against SARS-CoV-2—Preliminary Report. N. Engl. J. Med. 2020, 383, 1920–1931. [CrossRef] [PubMed]
4. Zhu, F.-C.; Guan, X.-H.; Li, Y.-H.; Huang, J.-Y.; Jiang, T.; Hou, L.-H.; Li, J.-X.; Yang, B.-F.; Wang, L.; Wang, W.-J.; et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020, 396, 479–488. [CrossRef]
5. Mulligan, M.J.; Lyke, K.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K.A.; et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020, 586, 589–593. [CrossRef] [PubMed]
6. Bos, R.; Rutten, L.; van der Lubbe, J.E.M.; Bakkers, M.J.G.; Hardenberg, G.; Wegmann, F.; Zuidgeest, D.; de Wilde, A.H.; Koornneef, A.; Verwilligen, A.; et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020, 5, 1–11. [CrossRef] [PubMed]
7. Stephenson, K.E.; Le Gars, M.; Sadow, J.; de Groot, A.M.; Heerwegh, D.; Truyers, C.; Atyeo, C.; Loos, C.; Chandrashekar, A.; McMahen, K.; et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID. JAMA 2021, 325, 1535. [CrossRef] [PubMed]
8. Sadow, J.; Le Gars, M.; Shukarev, G.; Heerwegh, D.; Truyers, C.; de Groot, A.M.; Stoop, J.; Tete, S.; Van Damme, W.; Leroux-Roels, I.; et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N. Engl. J. Med. 2021, 384, 1824–1835. [CrossRef] [PubMed]
9. Anderson, E.J.; Rouphael, N.G.; Widge, A.T.; Jackson, L.A.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Prijssers, A.J.; et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N. Engl. J. Med.* 2020, 383, 2427–2438. [CrossRef]

10. Walsh, E.E.; French, R.W., Jr.; Falsey, A.R.; Kitchin, N.; Absalon, J.; Kurtman, A.; Lockhart, S.; Neuzil, K.; Mulligan, M.J.; Bailey, R.; et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. *N. Engl. J. Med.* 2020, 383, 2439–2450. [CrossRef]

11. Lazarus, R.; Baos, S.; Cappel-Porter, H.; Carson-Stevens, A.; Clout, M.; Culliford, J.; Emmett, S.R.; Garstang, J.; Gbadamosi, L.; Hallis, B.; et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. *Lancet* 2021, 398, 2277–2287. [CrossRef]

12. Medeiros-Ribeiro, A.C.; Aikawa, N.E.; Saad, C.G.S.; Yuki, E.F.N.; Pedrosa, T.; Fusco, S.R.G.; Rojo, P.T.; Pereira, R.M.R.; Shinjo, S.K.; Andrade, D.C.O.; et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: A phase 4 trial. *Nat. Med.* 2021, 27, 1744–1751. [CrossRef] [PubMed]

13. Furer, V.; Eviatar, T.; Zisman, D.; Peleg, H.; Paran, D.; Levartovsky, D.; Zisapel, M.; Elalouf, O.; Kaufman, I.; Meidan, R.; et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. *Ann. Rheum. Dis.* 2021, 80, 1330–1338. [CrossRef] [PubMed]

14. Shinjo, S.K.; de Souza, F.H.C.; Borges, I.B.P.; dos Santos, A.M.; Mioskii, R.; Misse, R.G.; Medeiros-Ribeiro, A.C.; Saad, C.G.S.; Yuki, E.F.N.; Pasoto, S.G.; et al. Systemic autoimmune myopathies: A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. *Rheumatology* 2021. *Epub ahead of print*. [CrossRef]

15. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Ingleby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020, 584, 430–436. [CrossRef] [PubMed]

16. Rutherford, M.A.; Scott, J.; Karabayas, M.; Antonelou, M.; Gopaluni, S.; Gray, D.; Barrett, J.; Brix, S.R.; Dhaun, N.; McAdoo, S.P.; et al. Risk Factors for Severe Outcomes in Patients with Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. *Arthritis Rheumatol.* 2021, 73, 1713–1719. [CrossRef]

17. Ahmed, S.; Gasparyan, A.Y.; Zimba, O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. *Rheumatol. Int.* 2021, 41, 243–256. [CrossRef]

18. Arnold, J.; Winthrup, K.; Emery, P. COVID-19 vaccination and antirheumatic therapy. *Rheumatology* 2021, 60, 3496–3502. [CrossRef]

19. Prendecki, M.; Clarke, C.; Edwards, H.; McIntyre, S.; Mortimer, P.; Gleeson, S.; Martin, P.; Thomson, T.; Randell, P.; Shah, A.; et al. Humoral and T-cell responses to SARS-CoV-2 vaccine in patients receiving immunosuppression. *Ann. Rheum. Dis.* 2021, 80, 1322–1329. [CrossRef]

20. Malipiero, G.; Moratto, A.; Infantino, M.; D’Agaro, P.; Piscianz, E.; Manfredi, M.; Grossi, V.; Benvenuti, E.; Bulgaresi, M.; Benucci, M.; et al. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. *Immunol. Res.* 2021, 69, 576–583. [CrossRef]

21. Vijenthira, A.; Gong, I.; Betschel, S.D.; Cheung, M.; Hicks, L.K. Vaccine response following anti-CD20 therapy: A systematic review and meta-analysis of 905 patients. *Blood Adv.* 2021, 5, 2624–2643. [CrossRef] [PubMed]

22. Geisen, U.M.; Berner, D.K.; Tran, F.; Sümübil, M.; Vollriede, L.; Ciripoi, M.; Reid, H.M.; Schaffarzyk, A.; Longardt, A.C.; Franzenburg, J.; et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. *Ann. Rheum. Dis.* 2021, 80, 1306–1311. [CrossRef] [PubMed]

23. DerSimianon, R.; Laird, M. Meta-analysis in clinical trials. *Control Clin. Trials* 1986, 7, 177–188. [CrossRef]

24. Dimopoulou, D.; Spyridis, N.; Vartelis, G.; Tsiloi, M.N.; Maritsi, D.N. Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. *Arthritis Rheumatol.* 2021, 74, 365–366. [CrossRef]

25. Ammitzbøll, C.; Bartels, L.E.; Andersen, J.B.; Vils, S.R.; Mistegaard, C.E.; Johannsen, A.D.; Hermansen, M.-L.F.; Thomsen, M.K.; Hauge, E.; Trolldborg, A. Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis. *Acr Open Rheumatol.* 2021, 3, 622–628. [CrossRef]

26. Dimopoulou, D.; Vartelis, G.; Dasoula, F.; Tsolia, M.; Maritsi, D. Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. *Ann. Rheum. Dis.* 2021, 81, 592–593. [CrossRef]

27. Bartels, L.E.; Ammitzbøll, C.; Andersen, J.B.; Vils, S.R.; Mistegaard, C.E.; Johannsen, A.D.; Hermansen, M.-L.F.; Thomsen, M.K.; Erikstrup, C.; Hauge, E.-M.; et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. *Rheumatol. Int.* 2021, 41, 1925–1931. [CrossRef]

28. Benucci, M.; Damiani, A.; Infantino, M.; Manfredi, M.; Grossi, V.; Lari, B.; Gobbi, F.L.; Sarzi-Puttini, P. Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab. *Immunol. Res.* 2021, 69, 309–311. [CrossRef]

29. Bixio, R.; Bertelle, D.; Masia, M.; Pistillo, F.; Carletto, A.; Rossini, M. Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients with Rheumatoid Arthritis in Remission. *Acr Open Rheumatol.* 2021, 3, 832–833. [CrossRef]

30. Boekel, L.; Kummer, L.Y.; van Dam, K.P.J.; Hooijberg, F.; van Kempen, Z.; Vogelzang, E.H.; Wieske, L.; Eftimov, F.; van Vollenhoven, R.; Kuipers, T.W.; et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. *Lancet Rheumatol.* 2021, 3, e542–e545. [CrossRef]
31. Boekel, L.; Steenhuis, M.; Hooijberg, F.; Besten, Y.R.; van Kempen, Z.L.E.; Kummer, L.Y.; van Dam, K.P.J.; Stalman, E.W.; Vogelzang, E.H.; Christianawati, O.; et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: A study of data from two prospective cohort studies. *Lancet Rheumatol*. 2021, 3, e778–e788. [CrossRef]

32. Boyarsky, B.J.; Ruddy, J.A.; Connolly, C.M.; Ou, M.T.; Werbel, W.A.; Garonzik-Wang, J.M.; Segev, D.L.; Paik, J.J. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. *Ann. Rheum. Dis.* 2021, 80, 1098–1099. [CrossRef] [PubMed]

33. Braun-Moscovici, Y.; Kaplan, M.; Braun, M.; Markovits, D.; Giryes, S.; Toledano, K.; Tavor, Y.; Donlikov, K.; Balbir-Gurman, A. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. *Ann. Rheum. Dis.* 2021, 80, 1317–1321. [CrossRef] [PubMed]

34. Bugatti, S.; De Stefano, L.; Balduzzii, S.; Greco, M.I.; Luvare, T.; Cassaniti, I.; Bogliolo, L.; Mazzucchelli, I.; D’Onofrio, B.; di Lernia, M.; et al. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. *Ann. Rheum. Dis.* 2021, 80, 17–19. [CrossRef] [PubMed]

35. Cherian, S.; Paul, A.; Ahmed, S.; Alias, B.; Manoj, M.; Santhosh, A.K.; Varghese, D.R.; Krishnan, N.; Shenoy, P. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: A post-vaccination cross-sectional survey. *Rheumatol. Int.* 2021, 41, 1441–1445. [CrossRef] [PubMed]

36. Chiang, T.P.; Connolly, C.M.; Ruddy, J.A.; Boyarsky, B.J.; Alejo, J.L.; Werbel, W.A.; Massie, A.; Christopher-Stine, L.; Garonzik-Wang, J.; Segev, D.L.; et al. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. *Ann. Rheum. Dis.* 2021, 80, 1365–1366. [CrossRef]

37. Connolly, C.M.; Ruddy, J.A.; Boyarsky, B.J.; Barbier, I.; Werbel, W.A.; Geetha, D.; Garonzik-Wang, J.M.; Segev, D.L.; Christopher-Stine, L.; Paik, J.J. Disease flare and Reactogenicity in Patients with Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. *Arthritis Rheumatol.* 2021, 74, 28–32. [CrossRef] [PubMed]

38. Atteno, M.; Raimondo, M.; Mangiacapra, S.; Cannavacciuolo, F.; Nunziata, M.; Iorio, V.; Iuliano, N.; Tibullo, L.; Mastroianni, M.; Amitrano, M. Safety profile of pfizer-biontech covid-19 vaccine in patients with rheumatic diseases: Preliminary assessment. *Ann. Rheum. Dis.* 2021, 80, 907–908. [CrossRef] [PubMed]

39. Deepak, M.P.; Kim, W.; Paley, M.A.; Yang, M.; Carvidi, B.A.B.; Demissie, B.E.G.; El-Qunni, B.A.A.; Haile, B.A.; Huang, B.K.; Kinnett, B.B.; et al. Effect of Immunompression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. *Ann. Intern. Med.* 2021, 174, 1572–1579. [CrossRef] [PubMed]

40. Delvino, P.; BozzaUi Cassione, E.; Biglia, A.; Manoj, M.; Santhosh, A.K.; Varghese, D.R.; Krishnan, N.; Shenoy, P. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: A post-vaccination cross-sectional survey. *Rheumatol. Int.* 2021, 41, 1441–1445. [CrossRef] [PubMed]

41. Embi, P.J.; Levy, M.E.; Naleway, A.L.; Patel, P.; Gaglani, M.; Natarajan, K.; Dascomb, K.; Ong, T.C.; Klein, N.P.; Liao, I.-C.; et al. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: A cross-sectional study. *Rheumatol. Int.* 2021, 41, 2105–2108. [CrossRef] [PubMed]

42. Esquivel-Valerio, J.A.; Skinner-Taylor, C.M.; Moreno-Arquiesta, I.A.; la Garza, J.A.C.-D.; Garcia-Arellano, G.; Gonzalez-Garcia, P.L.; Almaraz-Juarez, F.; d.R.; Galarza-Delgado, D.A. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: Nine States, January–September 2021. *Morb. Mortal. Wkly. Rep.* 2021, 70, 1553–1559. [CrossRef]

43. Ferri, C.; Ursini, F.; Gragnani, L.; Raimondo, M.; Giuggioli, D.; Foti, R.; Caminiti, M.; Olivo, D.; Cuomo, G.; Visentini, M.; et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. *J. Autoimmun.* 2021, 125, 102744. [CrossRef]

44. Firunin, D.; Perra, A.; Campagna, M.; Littera, R.; Fenu, G.; Meloni, F.; Cipri, S.; Sella, F.; Conti, M.; Miglianti, M.; et al. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. *Clin. Exp. Rheumatol.* 2021, Epub ahead of print. [CrossRef] [PubMed]

45. Fragoulis, G.E.; Bournia, V.K.; Mavrea, E.; Evangelatos, G.; Fragiadaki, K.; Karamanakos, A.; Kravariti, E.; Laskari, K.; Panopoulos, S.; Pappa, M.; et al. COVID-19 vaccine safety and nocebo-prone associated hesitancy: A cross-sectional study. *Rheumatol. Int.* 2021, 42, 31–39. [CrossRef]

46. Haberman, R.H.; Herati, R.; Simon, D.; Samanovic, M.; Blank, R.B.; Tuen, M.; Koralov, S.B.; Atreye, R.; Tasclar, K.; Allen, J.R.; et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. *Ann. Rheum. Dis.* 2021, 80, 1–6. [CrossRef] [PubMed]

47. Izmirly, P.M.; Kim, M.Y.; Samanovic, M.; Fernandez-Ruiz, R.; Ohana, S.; Deonaraine, K.K.; Engel, A.J.; Masson, M.; Xie, X.; Cornelius, A.R.; et al. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. *Arthritis Rheumatol.* 2021, 74, 284–294. [CrossRef]

48. Kant, S.; Ravi, S.; Geetha, D. The SARS-CoV-2 Vaccine Response in ANCA-Associated Vasculitis. *J. Am. Soc. Nephrol.* 2021, 32, PO0148.

49. Li, X.; Tong, X.; Yeung, W.W.Y.; Kuan, P.; Tso, S.H.; Chui, C.S.L.; Lai, T.T.T.; Wan, E.Y.F.; Wong, C.K.H.; Chan, E.W.Y.; et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. *Ann. Rheum. Dis.* 2021, 81, 564–568. [CrossRef] [PubMed]
50. Machado, P.M.; Lawson-Tovey, S.; Hyrich, K.; Carmona, L.; Gossec, L.; Mateus, E.; Strangfeld, A.; Raffeiner, B.; Goulenok, T.; Brocq, O.; et al. Mariette COVID-19 vaccine safety in patients with rheumatoid and musculoskeletal disease. *Ann. Rheum. Dis.* 2021, 80, 199–200. [CrossRef]

51. Moyon, Q.; Sterlin, D.; Miyara, M.; Anna, F.; Mathian, A.; Lhote, R.; Ghillani-Dalbin, P.; Brelillat, P.; Mudumba, S.; de Alba, S.; et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. *Ann. Rheum. Dis.* 2021, 81, 575–583. [CrossRef]

52. Mrak, D.; Tohucic, S.; Koblischke, M.; Graninger, M.; Radner, H.; Sieghart, D.; Hofer, P.; Perkmann, T.; Haslacher, H.; Thallhammer, R.; et al. SARS-CoV-2 vaccine reaction in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. *Ann. Rheum. Dis.* 2020, 80, 1345–1350. [CrossRef] [PubMed]

53. Papagoras, C.; Fragoulis, G.E.; Zioja, N.; Simopoulou, T.; Deftereou, K.; Kalavri, E.; Zampeli, E.; Gerolymatou, N.; Kataxaki, E.; Melissaropoulos, K.; et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. *Ann. Rheum. Dis.* Epub ahead of print 2021. [CrossRef] [PubMed]

54. Picchianti-Diamanti, A.; Aiello, A.; Laganà, B.; Agrati, C.; Castilletti, C.; Meschi, S.; Farroni, C.; Lapa, D.; Fard, S.N.; Cuzzi, G.; et al. Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. *Front. Immunol.* 2021, 12, 740249. [CrossRef]

55. Rotondo, C.; Cantatore, F.; Forcaro, M.; Colia, R.; Busto, G.; Rella, V.; Sciaccà, S.; Lops, L.; Cici, D.; Maruotti, N.; et al. Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study. *Vaccines* 2021, 9, 730. [CrossRef] [PubMed]

56. Rubbert-Roth, A.; Vuilleumier, N.; Ludewig, B.; Schmiedeck, K.; Haller, C.; von Kempis, J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. *Lancet Rheumatol.* 2021, 3, e470–e472. [CrossRef]

57. Ruddy, J.A.; Connolly, C.M.; Boyarsky, B.J.; Werbel, W.A.; Christopher-Stine, L.;aronzic-Wang, J.; Segev, D.L.; Paik, J.J. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatoid and musculoskeletal diseases. *Ann. Rheum. Dis.* 2021, 80, 1351–1352. [CrossRef]

58. Sattui, S.E.; Liew, J.W.; Kennedy, K.; Sirotich, E.; Putman, M.; Moni, T.T.; Akpabio, A.; Alpizar-Rodriguez, D.; Berenbaum, F.; Bulpina, I.; et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Study. *RMD Open* 2021, 7, e001814. [CrossRef]

59. Schmiedeck, K.; Vuilleumier, N.; Pagano, S.; Albrich, W.C.; Ludewig, B.; von Kempis, J.; Rubbert-Roth, A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. *Lancet Rheumatol.* 2021, 4, e11–e13. [CrossRef]

60. Sciascia, S.; Costanzo, P.; Radin, M.; Schreiber, K.; Pini, M.; Vaccarino, A.; Cecchi, I.; Baldovino, S.; Roccatello, D. Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies. *Lancet Rheumatol.* 2021, 3, e832. [CrossRef]

61. Seyahi, E.; Bakhdiyari, G.; Oztas, M.; Kuskucu, M.A.; Tok, Y.; Kut, N.; Ozciftci, G.; Ozcaglayan, A.; Balkan, I.I.; Saltoglu, N.; et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: A controlled study among hospital workers and elderly. *Rheumatol. Int.* 2021, 41, 1429–1440. [CrossRef]

62. Simon, D.; Tascilar, K.; Krönke, G.; Kleyer, A.; Zais, M.M.; Hepp, F.; Meder, C.; Atrey, R.; Klenske, E.; Dietrich, P.; et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. *Nat. Commun.* 2020, 11, 3774. [CrossRef] [PubMed]

63. Tzioufas, A.G.; Bakasis, A.-D.; Goules, A.V.; Bitzogli, K.; Cinoku, I.; Chatzis, L.G.; Argyropoulou, O.D.; Venetsanopoulou, A.; Mavrommatis, A.; et al. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. *J. Autoimmun.* 2021, 125, 102743. [CrossRef] [PubMed]

64. Yang, M.; Katz, P.; Paez, D.; Carvidi, A.; Matloubian, M.; Nakamura, M.; Gensler, L.S.; Gensler Reactogenicity of SARS-COV-2 vaccines in patients with autoimmune and inflammatory disease. *Ann. Rheum. Dis.* 2021, 80, 911. [CrossRef]

65. Zavala-Flores, E.; Salcedo-Matienzo, J.; Quiroz-Alva, A.; Berrocal-Kasay, A. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. *Clin. Rheumatol.* 2021, 1–9. [CrossRef]

66. Attauabi, M.; Seidelin, J.B.; Felding, O.K.; Weyer, M.D.; Arp, L.K.V.; Sariayka, M.A.; Egeberg, A.; Vladimirova, N.; Bendtsen, F.; Burisch, J. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. *J. Autoimmun.* 2021, 118, 102613. [CrossRef] [PubMed]

67. Curtis, J.R.; Johnson, S.R.; Anthony, D.D.; Arasaratrnam, R.J.; Baden, L.R.; Bass, A.R.; Calabrese, C.; Gravallese, E.M.; Harpaz, R.; Kroger, A.; et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: Version 3. *Arthritis Rheumatol.* 2021, 73, e60–e75. [CrossRef] [PubMed]

68. Furer, V.; Rondaan, C.; Heijstek, M.W.; Agmon-Levin, N.; Van Assen, S.; Bijl, M.; Breedveld, F.C.; D’Amelio, R.; Dougados, M.; Kapetanovic, M.C.; et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann. Rheum. Dis.* 2020, 79, 39–52. [CrossRef]

69. Hua, C.; Barnette, T.; Combe, B.; Morel, J. Effect of Methotrexate, Anti-Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Arthritis Care Res.* 2014, 66, 1016–1026. [CrossRef]
70. Grupper, A.; Rabinowich, L.; Schwartz, D.; Schwartz, I.F.; Ben-Yehoyada, M.; Shashar, M.; Katchman, E.; Halperin, T.; Turner, D.; Goykhman, Y.; et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *Arab. Archaeol. Epigr.* 2021, 21, 2719–2726. [CrossRef]

71. Peled, Y.; Ram, E.; Lavee, J.; Sternik, L.; Segev, A.; Wieder-Finesod, A.; Mandelboim, M.; Indenbaum, V.; Levy, I.; Raanani, E.; et al. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response. *J. Heart Lung Transplant.* 2021, 40, 759–762. [CrossRef]

72. Felten, R.; Dubois, M.; Ugarte-Gil, M.F.; Chaudier, A.; Kawka, L.; Bergier, H.; Costecalde, C.; Pijnenburg, L.; Fort, J.; Chatelus, E.; et al. Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. *Lancet Rheumatol.* 2021, 3, e243–e245. [CrossRef]

73. Wu, Q.; Dudley, M.Z.; Chen, X.; Bai, X.; Dong, K.; Zhuang, T.; Salmon, D.; Yu, H. Evaluation of the safety profile of COVID-19 vaccines: A rapid review. *BMC Med.* 2021, 19, 173. [CrossRef] [PubMed]

74. Capone, F.; Lucchini, M.; Ferraro, E.; Bianco, A.; Rossi, M.; Cicia, A.; Cortese, A.; Cruciani, A.; De Arcangelis, V.; De Giglio, L.; et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. *Neurotherapeutics* 2021, 1–9. [CrossRef] [PubMed]

75. Sormani, M.P.; Schiavetti, I.; Landi, D.; Carmisciano, L.; De Rossi, N.; Cordioli, C.; Moiola, L.; Radaelli, M.; Immovilli, P.; Capobianco, M.; et al. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. *Mult. Scler. J.* 2021, 13524858211035318. [CrossRef] [PubMed]